Dasiglucagon (Zegalogue)

Dasiglucagon is a chemically stabilized glucagon analog — not simply a new delivery device for native glucagon — that completes the ready-to-use rescue-glucagon cluster alongside this site's Glucagon page (which covers Baqsimi's nasal powder and Gvoke's ready-to-use native-sequence liquid). The FDA approved it in 2021 on a genuine three-trial Phase 3 program, and it's now also in late-stage testing as the glucagon half of a fully automated dual-hormone artificial pancreas.

A stable analog, not just a new formulation of native glucagon

Native human glucagon is chemically unstable once dissolved in water: above roughly pH 3, the 29-amino-acid peptide self-aggregates ("fibrillates") within hours to days, which is exactly why the traditional emergency glucagon kits this site's Glucagon page describes were sold as a powder that a caregiver had to reconstitute with a separate diluent in the middle of an emergency — a real, documented source of dosing errors and delay. Dasiglucagon (Zegalogue, developed by Zealand Pharma) solves that problem at the molecular level rather than through a delivery-device workaround: it substitutes seven of glucagon's 29 amino acids, specifically chosen to disrupt the self-aggregation pathway while preserving the molecule's ability to bind and activate the glucagon receptor. The result is a peptide that stays soluble and stable as a ready-to-use liquid, at room temperature, in a prefilled syringe or autoinjector — a genuinely different engineering approach from Gvoke's stabilizing formulation of the native glucagon sequence itself.

How it differs from this site's Glucagon page

This site's existing Glucagon page covers the original reconstituted emergency kits, Baqsimi (intranasal powdered native glucagon, approved 2019) and Gvoke (ready-to-use liquid native glucagon, approved 2019-2021 across its device forms) — all three delivering the same 29-amino-acid native glucagon sequence through different formulations or routes. Dasiglucagon is the molecule those three pages don't cover: a structurally modified analog, not native glucagon at all, developed and approved separately as its own product rather than a new formulation folded into an existing one. It shares the same rescue-hypoglycemia use case and the same general "ready-to-use, no reconstitution" convenience Gvoke offers, but by a different chemical route.

The Phase 3 program

Dasiglucagon's approval rested on three randomized, double-blind, placebo-controlled Phase 3 trials. The pivotal adult trial (Pieber TR, Aronson R, Hövelmann U, et al., "Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial," Diabetes Care 2021;44(6):1361-1367, DOI 10.2337/dc20-2995) randomized 170 adults with type 1 diabetes, 2:1:1, to a single 0.6mg dose of dasiglucagon, placebo, or 1mg reconstituted native glucagon during controlled insulin-induced hypoglycemia. Median time to glucose recovery was 10 minutes with dasiglucagon versus 40 minutes with placebo (p<0.001) and 12 minutes with reconstituted glucagon, with 99% of the dasiglucagon group recovering within 15 minutes versus 2% on placebo and 95% on reconstituted glucagon. A companion pediatric trial in children and adolescents ages 6-17 (Battelino T, et al., Pediatr Diabetes 2021) and a separate autoinjector-device trial in adults (Bailey TS, et al., Diabetes Obes Metab 2021) found consistent results. The FDA approved Zegalogue on 22 March 2021 for severe hypoglycemia in patients ages 6 and up, and Zealand Pharma launched it in the US that June, in both prefilled-syringe and autoinjector forms.

A second act: the glucagon half of a dual-hormone artificial pancreas

Beta Bionics received FDA 510(k) clearance for its iLet Bionic Pancreas in May 2023, a device platform explicitly designed to be configurable as an insulin-only, glucagon-only, or bihormonal (insulin-and-glucagon) automated delivery system — but that initial 2023 clearance covered the insulin-only configuration. The bihormonal configuration, which is designed to use dasiglucagon specifically as its glucagon component, requires both a separate FDA marketing application for that device configuration and a new drug application covering dasiglucagon's use in a continuous pump infusion, a materially different use than its approved single-dose rescue-pen indication; Beta Bionics has been running a pivotal trial toward that combined filing, but as of this review the bihormonal configuration has not received FDA clearance — worth checking against a current source before assuming it has launched.

Current status

Zegalogue remains FDA-approved and marketed in the US for its original severe-hypoglycemia rescue indication. In September 2022, Zealand Pharma licensed global commercialization rights to Novo Nordisk, which now markets Zegalogue in the US while Zealand continues supporting development and approval outside the US; Zealand retains the separate congenital hyperinsulinism and artificial-pancreas programs described above. As a prescription rescue and pump-infusion product used only under medical supervision, dasiglucagon carries no wellness, cosmetic or grey-market use of any kind.